Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.

• Publication year

  2017

• Venue

  International Journal of Molecular Sciences

• Publication date

  2017-06-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms18071338PMID 28640192PMCID 5535831
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pancreatic cancer.

  2021cited by this paper
• Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.

  2019cited by this paper
• Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

  2017cited by this paper
• CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.

  2017cited by this paper
• Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials

  2017cited by this paper
• Genomic analyses identify molecular subtypes of pancreatic cancer

  2016cited by this paper
• Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.

  2016cited by this paper
• Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

  2016cited by this paper
• Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.

  2016cited by this paper
• Pancreatic Cancer from Molecular Pathways to Treatment Opinion

  2016cited by this paper
• Ipilimumab and gemcitabine for advanced pancreas cancer: A phase Ib study .

  2016cited by this paper
• Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

  2016cited by this paper
• Pancreatic cancer: Current research and future directions.

  2016cited by this paper
• PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.

  2016cited by this paper
• Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

  2016cited by this paper
• Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

  2016cited by this paper
• MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer

  2016cited by this paper
• The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer

  2016cited by this paper
• Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.

  2016cited by this paper
• DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

  2016cited by this paper
• The role of neoadjuvant therapy in pancreatic cancer: a review.

  2016cited by this paper
• Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

  2015cited by this paper
• nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

  2015cited by this paper
• Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia

  2015cited by this paper
• Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

  2015cited by this paper
• Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

  2015cited by this paper
• Recent advances in pancreatic cancer: biology, treatment, and prevention.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability

  2015cited by this paper
• Treatment of patients with metastatic pancreatic cancer: Experience from a tertiary Indian cancer center.

  2015cited by this paper
• Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

  2015cited by this paper
• A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

  2015cited by this paper
• Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.

  2015cited by this paper
• MEK and PI3K inhibition in solid tumors: rationale and evidence to date

  2015cited by this paper
• A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

  2015cited by this paper
• Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.

  2015cited by this paper
• Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.

  2015cited by this paper
• A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

  2015cited by this paper
• High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.

  2015influential reference
• Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

  2015cited by this paper
• Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer

  2015cited by this paper
• Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

  2015cited by this paper
• JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy.

  2015cited by this paper
• Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.

  2015cited by this paper
• CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study.

  2015cited by this paper
• Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer

  2015cited by this paper
• Novel directions in neoadjuvant therapy for pancreas adenocarcinoma

  2015cited by this paper
• Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

  2015cited by this paper
• Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked

  2015cited by this paper
• The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome

  2015cited by this paper
• Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

  2014cited by this paper
• Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

  2014cited by this paper
• FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

  2014cited by this paper
• Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis

  2014cited by this paper
• 747TiPSCHEDULING NAB-PACLITAXEL WITH GEMCITABINE (SIEGE): RANDOMISED PHASE II TRIAL TO INVESTIGATE TWO DIFFERENT SCHEDULES OF NAB-PACLITAXEL (ABX) COMBINED WITH GEMCITABINE (GEM) AS FIRST LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA (PDAC).

  2014cited by this paper
• A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

  2014cited by this paper
• Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.

  2014cited by this paper
• Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy

  2014cited by this paper
• Genistein inhibits cell growth and invasion through regulation of miR-27a in pancreatic cancer cells.

  2014cited by this paper
• Oncogenic KRAS signalling in pancreatic cancer

  2014cited by this paper
• Influence of preoperative anti‐cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery

  2014cited by this paper
• Borderline resectable pancreatic cancer: definitions and management.

  2014cited by this paper
• Deep Sequencing of RNA from Three Different Extracellular Vesicle (EV) Subtypes Released from the Human LIM1863 Colon Cancer Cell Line Uncovers Distinct Mirna-Enrichment Signatures

  2014cited by this paper
• Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

  2014cited by this paper
• Pancreatic cancer and its stroma: a conspiracy theory.

  2014cited by this paper
• A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

  2014cited by this paper
• Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer

  2014cited by this paper
• Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.

  2014cited by this paper
• Management of borderline resectable pancreatic cancer.

  2014cited by this paper
• MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens

  2014cited by this paper
• Treatment of metastatic pancreatic adenocarcinoma: a review.

  2014cited by this paper
• Expression of MicroRNA-15b and the Glycosyltransferase GCNT3 Correlates with Antitumor Efficacy of Rosemary Diterpenes in Colon and Pancreatic Cancer

  2014cited by this paper
• Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

  2014cited by this paper
• Neoadjuvant Therapy and Vascular Resection During Pancreaticoduodenectomy: Shifting the Survival Curve for Patients with Locally Advanced Pancreatic Cancer

  2014cited by this paper
• Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions.

  2014cited by this paper
• Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

  2014cited by this paper
• Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer

  2014cited by this paper
• Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).

  2014cited by this paper
• Alteration of the microRNA expression profile during the activation of pancreatic stellate cells

  2014influential reference
• Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer

  2014cited by this paper
• Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer

  2014cited by this paper
• S-1 in the treatment of pancreatic cancer.

  2014cited by this paper
• O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

  2014cited by this paper
• A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2

  2013cited by this paper
• Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

  2013cited by this paper
• A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

  2013cited by this paper
• CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer

  2013cited by this paper
• Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

  2013cited by this paper
• MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3.

  2013cited by this paper
• Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression

  2013cited by this paper
• Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

  2013cited by this paper
• Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma

  2013cited by this paper
• Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial

  2013cited by this paper
• Expression of MicroRNAs in Patients With Pancreatic Cancer and Its Prognostic Significance

  2013cited by this paper
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

  2013cited by this paper
• Evolution and dynamics of pancreatic cancer progression

  2013cited by this paper
• Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

  2013cited by this paper

• A Streamlined Protocol for Developing a Clinicopathological Prediction Model for Patient Survival of Post‐Resection of Pancreatic Cancer

  2026cites this paper
• Radiomic features of CECT and SUVmax of dual-tracer PET/CT reveal PD-L1 spatial heterogeneity in PDAC.

  2026cites this paper
• IKBKE downregulation increases chemosensitivity through pyroptosis mediated by the caspase-3/GSDME pathway in pancreatic cancer.

  2026cites this paper
• NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis

  2026cites this paper
• Mechanistic insights into miR-4775-mediated regulation of pancreatic cancer cell invasion and migration through BRMS1L

  2026cites this paper
• Informed spatially aware patterns for multiplexed immunofluorescence data

  2026cites this paper
• Global trends and future predictions of pancreatic cancer incidence and mortality from 1990 to 2030: A comparative analysis of China, Korea, Japan, and the USA

  2025cites this paper
• Calcium hydroxide nanoparticles induce apoptotic cell death in human pancreatic cancer cells through over ROS-driven genomic instability and mitochondrial dysfunction

  2025cites this paper
• Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma

  2025influential citation
• MICLEAR: Intelligent Molecular Cytology for Intraoperative Margin Assessment of Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Strategic Design and Development of Indole‐Based Compounds as Potent Malic Enzyme 3 Inhibitors for Pancreatic Tumor Therapy

  2025cites this paper
• CT-based radiomics models decode fibrosis content and molecular differences in pancreatic ductal adenocarcinoma: a multi-institutional study

  2025cites this paper
• Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.

  2025cites this paper
• Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway.

  2025cites this paper
• CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer

  2025cites this paper
• Novel Insights into T-Cell Exhaustion and Cancer Biomarkers in PDAC Using ScRNA-Seq

  2025cites this paper
• Bispecific Siglec-15/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors in vivo

  2025cites this paper
• Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and endoscopic ultrasound-guided ethanol ablation (EUS-EA) of pancreatic neuroendocrine tumors and adenocarcinoma: a prospective multicenter study

  2025cites this paper
• Synchronous Pancreatic Neoplasms Involving Pancreatic Ductal Adenocarcinoma: A Systematic Review of Case Reports

  2025cites this paper
• Fast-Relaxing Hydrogels Promote Pancreatic Adenocarcinoma Cell Aggressiveness through Integrin β1 Signaling

  2025cites this paper
• The supporting role of Schwann cells in perineural invasion of pancreatic ductal adenocarcinoma

  2025cites this paper
• Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies

  2025cites this paper
• Decoding the pancreatic cancer microenvironment: The multifaceted regulation of microRNAs

  2025cites this paper
• Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

  2025cites this paper
• Cannabidiol Is Associated with Improved Survival in Pancreatic Cancer and Modulation of Bile Acids and Gut Microbiota

  2025cites this paper
• PERFIL EPIDEMIOLÓGICO DA NEOPLASIA MALIGNA DE PÂNCREAS EM IDOSOS NO BRASIL: 2019 A 2024

  2025cites this paper
• Clinical translation and landscape of superparamagnetic iron oxide nanoparticles.

  2025cites this paper
• Bioengineering 3D Pancreatic Cancer Models with Fibrotic Stroma for In Vitro Cancer Modeling

  2025cites this paper
• Dynamic interaction of MYC enhancer RNA with YEATS2 protein regulates MYC gene transcription in pancreatic cancer

  2025cites this paper
• MRI and PET-Based Machine Learning Radiomics for Metastasis Prediction in Pancreatic Ductal Adenocarcinoma: A Systematic Review

  2025cites this paper
• Analytical Validation of a Serum Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma

  2025influential citation
• Effect of microbubble-assisted gemcitabine delivery with repeated ultrasound exposure in a pancreatic cancer organ-on-a-chip model

  2025cites this paper
• Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma

  2025cites this paper
• Self-emulsifying Nano-PND oral delivery systems of PND1186: In silico modeling for bioavailability estimation.

  2025cites this paper
• Computational Repurposing of Natural Compounds from Drimia indica, an Underutilized Medicinal Plant, for Targeting Src‐Mediated Pancreatic Cancer Pathways

  2025cites this paper
• Comparative Efficacy and Toxicity of Modified FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Analysis

  2025cites this paper
• Impact of Routine and Selective Preoperative Endoscopic Retrograde Cholangiopancreatography with Stent Placement on Postoperative and Oncologic Outcomes Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy.

  2025cites this paper
• Data independent acquisition mass spectrometry (DIA-MS) in cancer studies: a concise review.

  2025cites this paper
• Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma

  2025cites this paper
• Radiofrequency ablation of liver metastases in a patient with pancreatic cancer and long-term survival: A case report

  2025cites this paper
• tRF-Pro-CGG Suppresses Cell Proliferation and Promotes Apoptosis in Pancreatic Cancer

  2025cites this paper
• Unveiling Microbiota Profiles in Saliva and Pancreatic Tissues of Patients with Pancreatic Cancer

  2025cites this paper
• Multiomics in cancer biomarker discovery and cancer subtyping.

  2025cites this paper
• Tropisetron Suppresses Chronic Pancreatitis and Pancreatic Cancer by Blocking Interleukin 33 Expression

  2025cites this paper
• High-Precision Intelligent Diagnosis of Pancreatic Cancer: Flowing Diffuseness from Single to Whole.

  2025cites this paper
• Disseminated Superficial Actinic Porokeratosis in a Woman With Metastatic Pancreatic Cancer During Chemotherapy With Capecitabine and Nab-Paclitaxel.

  2025cites this paper
• Correlative Analysis of Tumor-Informed Circulating Tumor DNA (ctDNA) and the Survival Outcomes of Patients with Pancreatic Adenocarcinoma

  2025cites this paper
• Radiomics in Early Detection of Pancreatic Ductal Adenocarcinoma: A Close Look at Its Current Status and Challenges to Clinical Implementation

  2025cites this paper
• Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe

  2025cites this paper
• Patient-Derived 3D-Bioprinted models of pancreatic Cancer: Toward personalized therapy and overcoming tumor microenvironment challenges.

  2025cites this paper
• Berberine-loaded mesoporous silica nanomaterials inhibit pancreatic cancer targeting cancer stem cells.

  2025cites this paper
• Progress in undestanding of relationship between P2X7R and pancreatic ductal adenocarcinoma

  2025cites this paper
• Enhancing Early Detection of Pancreatic Cancer in Genetically Predisposed Individuals: Integrating Advanced Imaging Modalities with Emerging Biomarkers and Liquid Biopsy

  2025cites this paper
• Natural products and long noncoding RNA signatures in gallbladder cancer: a review focuses on pathogenesis, diagnosis, and drug resistance

  2024cites this paper
• Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer

  2024cites this paper
• Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine

  2024cites this paper
• Coexisting mechanisms of luminogenesis in pancreatic cancer-derived organoids

  2024cites this paper
• The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer.

  2024cites this paper
• The roles of E2F7 in cancer: Current knowledge and future prospects

  2024cites this paper
• Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy

  2024cites this paper
• Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Small molecular inhibitors: Therapeutic strategies for pancreatic cancer.

  2024cites this paper
• An mRNA vaccine for pancreatic cancer designed by applying in silico immunoinformatics and reverse vaccinology approaches

  2024cites this paper
• A Comparison of Tools That Identify Tumor Cells by Inferring Copy Number Variations from Single-Cell Experiments in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Prognostic significance of collagen signatures in pancreatic ductal adenocarcinoma obtained from second-harmonic generation imaging

  2024cites this paper
• Investigating the influence of taurochenodeoxycholic acid (TCDCA) on pancreatic cancer cell behavior: An RNA Sequencing Approach.

  2024cites this paper
• Urinary biomarkers analysis as a diagnostic tool for early detection of pancreatic adenocarcinoma: Molecular quantification approach

  2024cites this paper
• lncRNAs and cyclin-dependent kinases: Unveiling their critical roles in cancer progression.

  2024cites this paper
• A clinical-radiomics nomogram based on dual-layer spectral detector CT to predict cancer stage in pancreatic ductal adenocarcinoma

  2024cites this paper
• Bidirectional relationship between pancreatic cancer and diabetes mellitus: a comprehensive literature review

  2024cites this paper
• Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma

  2024cites this paper
• NIR Fluorescent/Photoacoustic Bimodal Imaging of Ferroptosis in Pancreatic Cancer Using Biothiols-Activable Probes.

  2024cites this paper
• Dysbiosis Signature of Fecal Microbiota in Patients with Pancreatic Adenocarcinoma and Pancreatic Intraductal Papillary Mucinous Neoplasms

  2024cites this paper
• The Dual Roles of S-Nitrosylation of Proteins in Cancer: Molecular Mechanisms and Recent Advancements

  2024cites this paper
• Synergistic Anticancer Activity of Plumbagin and Xanthohumol Combination on Pancreatic Cancer Models

  2024cites this paper
• Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers

  2024cites this paper
• NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation

  2024cites this paper
• Oral bacteria accelerate pancreatic cancer development in mice

  2024cites this paper
• Factors associated with radiological misstaging of pancreatic ductal adenocarcinoma: A retrospective observational study.

  2024cites this paper
• RAC1b Collaborates with TAp73α-SMAD4 Signaling to Induce Biglycan Expression and Inhibit Basal and TGF-β-Driven Cell Motility in Human Pancreatic Cancer

  2024cites this paper
• Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity

  2024cites this paper
• Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines

  2024cites this paper
• Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges

  2024cites this paper
• Pancreatic Adenocarcinoma: Imaging Modalities and the Role of Artificial Intelligence in Analyzing CT and MRI Images

  2024cites this paper
• Perspectives on chemotherapy-induced toxicities in pancreatic cancer

  2024cites this paper
• Epigenetic small-molecule screen for inhibition and reversal of acinar ductal metaplasia in mouse pancreatic organoids

  2024cites this paper
• BEYOND TRADITIONAL TOOLS: EXPLORING CONVOLUTIONAL NEURAL NETWORKS AS INNOVATIVE PROGNOSTIC MODELS IN PANCREATIC DUCTAL ADENOCARCINOMA.

  2024cites this paper
• Enhancement of in-vivo cellular uptake of Coenzyme Q10 using saponin derivatives in rTALAP transgenic mice model

  2024cites this paper
• Biological activity and computational analysis of novel acrylonitrile derived benzazoles as potent antiproliferative agents for pancreatic adenocarcinoma with antioxidative properties.

  2024cites this paper
• Exploring the value of multiparametric quantitative MRI in the assessment of pancreatic ductal adenocarcinoma fibrosis grading

  2024cites this paper
• Research advancements on the involvement of E3 ubiquitin ligase UBR5 in gastrointestinal cancers

  2024cites this paper
• An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum

  2024cites this paper
• Exosome-Based Advances in Pancreatic Cancer: The Potential of Mesenchymal Stem Cells.

  2024cites this paper
• Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review

  2024cites this paper
• Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma

  2024cites this paper
• Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells

  2024cites this paper
• Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma

  2024cites this paper
• The function of p97/valosin-containing protein (VCP) and small VCP-interacting protein (SVIP) in invasion and migration of pancreatic cancer cells

  2024cites this paper
• Evaluating the Association of Area Deprivation Index (ADI) on Postoperative Outcomes in Pancreatic Adenocarcinoma

  2024cites this paper